Last updated: March 24, 2009
Sponsor: AstraZeneca
Overall Status: Completed
Phase
3
Condition
Circulation Disorders
Williams Syndrome
Vascular Diseases
Treatment
N/AClinical Study ID
NCT00642096
D4026C00001
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diastolic blood pressure between 95 and 114 mm at screening and start of treatment
Exclusion
Exclusion Criteria:
Significant conditions which in the opinion of the investigator place the subject atundue risk, eg Renal impairment, hepatitis
Known secondary causes of hypertension, eg, Cushing's syndrome, renal artery stenosis,pheochromocytoma, hyperaldosteronism
Systolic blood pressure greater or equal to 180 mm Hg at start of trial
Study Design
Total Participants: 1900
Study Start date:
June 01, 2003
Estimated Completion Date:
July 31, 2004